Literature DB >> 22992983

Indications for use and safety of rituximab in childhood renal diseases.

Kjell Tullus1, Stephen D Marks.   

Abstract

Rituximab was initially developed for the treatment of patients with B cell lymphoma but has during the last decade proven to be quite effective in treating a range of kidney diseases including lupus nephritis, nephrotic syndrome, and also in different situations before and after a renal transplant. We will here review the scientific basis for the use of rituximab in children with renal diseases and give recommendations both regarding its clinical use and need for further research.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22992983     DOI： 10.1007/s00467-012-2260-3

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN： 0931-041X            Impact factor:   3.714


  57 in total

1.  Dense B cell infiltrates in paediatric renal transplant biopsies are predictive of allograft loss.

Authors:  Mordi R Muorah; Paul A Brogan; Neil J Sebire; Richard S Trompeter; Stephen D Marks
Journal:  Pediatr Transplant       Date:  2008-04-22

2.  Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma.

Authors:  J D Hainsworth; H A Burris; L H Morrissey; S Litchy; D C Scullin; J D Bearden; P Richards; F A Greco
Journal:  Blood       Date:  2000-05-15       Impact factor: 22.113

3.  Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.

Authors:  Cándido Díaz-Lagares; Sara Croca; Shirish Sangle; Edward M Vital; Fausta Catapano; Agustín Martínez-Berriotxoa; Francisco García-Hernández; José-Luis Callejas-Rubio; Javier Rascón; David D'Cruz; David Jayne; Guillermo Ruiz-Irastorza; Paul Emery; David Isenberg; Manuel Ramos-Casals; Munther A Khamashta
Journal:  Autoimmun Rev       Date:  2011-10-18       Impact factor: 9.754

4.  Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome.

Authors:  Kandai Nozu; Kazumoto Iijima; Masato Fujisawa; Atsuko Nakagawa; Norishige Yoshikawa; Masafumi Matsuo
Journal:  Pediatr Nephrol       Date:  2005-08-16       Impact factor: 3.714

5.  Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome.

Authors:  Aditi Sinha; Arvind Bagga; Ashima Gulati; Pankaj Hari
Journal:  Pediatr Nephrol       Date:  2011-09-16       Impact factor: 3.714

6.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Authors:  Sandra V Navarra; Renato M Guzmán; Alberto E Gallacher; Stephen Hall; Roger A Levy; Renato E Jimenez; Edmund K-M Li; Mathew Thomas; Ho-Youn Kim; Manuel G León; Coman Tanasescu; Eugeny Nasonov; Joung-Liang Lan; Lilia Pineda; Z John Zhong; William Freimuth; Michelle A Petri
Journal:  Lancet       Date:  2011-02-04       Impact factor: 79.321

7.  Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy.

Authors:  Kerstin Benz; Jörg Dötsch; Wolfgang Rascher; Daniel Stachel
Journal:  Pediatr Nephrol       Date:  2004-04-08       Impact factor: 3.714

8.  Implementation of a Protocol for ABO-incompatible kidney transplantation--a three-center experience with 60 consecutive transplantations.

Authors:  Gunnar Tydén; Johannes Donauer; Jonas Wadström; Gunilla Kumlien; Jochen Wilpert; Thomas Nilsson; Helena Genberg; Przemislaw Pisarski; Gunnar Tufveson
Journal:  Transplantation       Date:  2007-05-15       Impact factor: 4.939

9.  Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children.

Authors:  Koichi Kamei; Shuichi Ito; Kandai Nozu; Shuichiro Fujinaga; Makiko Nakayama; Mayumi Sako; Mari Saito; Maki Yoneko; Kazumoto Iijima
Journal:  Pediatr Nephrol       Date:  2009-05-07       Impact factor: 3.714

10.  Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.

Authors:  Mónica Vigna-Perez; Berenice Hernández-Castro; Octavio Paredes-Saharopulos; Diana Portales-Pérez; Lourdes Baranda; Carlos Abud-Mendoza; Roberto González-Amaro
Journal:  Arthritis Res Ther       Date:  2006-05-05       Impact factor: 5.156
View more
  6 in total

Review 1.  Why are kids with lupus at an increased risk of cardiovascular disease?

Authors:  Catherine Quinlan; Stephen D Marks; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2015-09-23       Impact factor: 3.714

Review 2.  Is rituximab effective in childhood nephrotic syndrome? Yes and no.

Authors:  Markus J Kemper; Anja Lehnhardt; Anna Zawischa; Jun Oh
Journal:  Pediatr Nephrol       Date:  2013-07-03       Impact factor: 3.714

3.  T Lymphocyte Activation Markers as Predictors of Responsiveness to Rituximab among Patients with FSGS.

Authors:  Chang-Yien Chan; Isaac Desheng Liu; Lourdes Paula Resontoc; Kar-Hui Ng; Yiong-Huak Chan; Perry Yew-Weng Lau; Mya Than; Stanley C Jordan; Kong-Peng Lam; Wee-Song Yeo; Hui-Kim Yap
Journal:  Clin J Am Soc Nephrol       Date:  2016-06-07       Impact factor: 8.237

4.  Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome.

Authors:  Hazel Webb; Graciana Jaureguiberry; Stephanie Dufek; Kjell Tullus; Detlef Bockenhauer
Journal:  Pediatr Nephrol       Date:  2015-11-02       Impact factor: 3.714

Review 5.  Steroid-sensitive nephrotic syndrome in children: triggers of relapse and evolving hypotheses on pathogenesis.

Authors:  Samuel N Uwaezuoke
Journal:  Ital J Pediatr       Date:  2015-03-21       Impact factor: 2.638

6.  Rituximab for Children With Difficult-to-Treat Nephrotic Syndrome: Its Effects on Disease Progression and Growth.

Authors:  Rezan Topaloğlu; Bora Gülhan; Kübra Çelegen; Mihriban İnözü; Mutlu Hayran; Ali Düzova; Fatih Ozaltin
Journal:  Front Pediatr       Date:  2019-07-30       Impact factor: 3.418
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.